Introduction
============

The rising prevalence of obesity has become a public health crisis in the United States during the past three decades. Between 1988 and 2012, prevalence of obesity increased from 10% to 17% in children and adolescents aged 2-19 years and from 23% to 35% in adults aged 20 years or older.[@ref1] [@ref2] [@ref3] Substantial data indicate tracking of childhood weight status into adulthood.[@ref4] Overweight children had a greater than twofold risk of becoming overweight adults compared with normal weight children. Therefore, a life course perspective is crucial to better understanding of the health consequences of overweight and obesity and to development of effective prevention strategies targeting the life period at which excess body weight has a predominant influence on future risk of disease or death.

Many studies have assessed the association between adult obesity, often assessed by body mass index (BMI), and risk of premature death.[@ref5] [@ref6] [@ref7] A recent meta-analysis of 97 studies using standard BMI categories reported that relative to normal weight (BMI 18.5-\<25), all cause mortality was increased for obesity (BMI ≥30) but was decreased for overweight (BMI 25-29).[@ref8] These data are far from conclusive owing to methodological limitations, particularly reverse causation by pre-existing illness and confounding by smoking, which may have contributed to the inverse association between overweight and mortality.[@ref9]

In contrast, the association of childhood or adolescent adiposity with adult mortality has been relatively less studied. Although high BMI in early life has been linked to increased mortality in most studies, whether this link is independent of adulthood BMI remains unclear.[@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] This question is challenging to answer, because adulthood BMI is likely to be on the causal path from childhood BMI to later disease.[@ref12] Statistical adjustment for adulthood BMI may introduce over-adjustment bias and make interpreting results difficult. Other techniques, such as analysis of different combinations of BMI groups (for example, obese versus non-obese) characterized over the life course, can result in loss of information due to discrete categorization.[@ref16]

Therefore, to extend our knowledge, we used a different, trajectory based approach to assess the relation between body shape in early and middle life and risk of all cause and cause specific mortality in two large US cohort studies. By classifying participants into distinct, mutually exclusive trajectory groups, our study allows a close scrutiny of the population heterogeneity in change in body shape over the life course and permits direct comparison of the mortality risk across these groups.

Methods
=======

Study population
----------------

The Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) are two ongoing US cohorts that respectively enrolled 121 700 registered female nurses aged 30-55 years in 1976 and 51 529 male health professionals aged 40-75 years in 1986. Similar follow-up procedures have been used in the two cohorts.[@ref17] [@ref18] Briefly, detailed questionnaires were administered at baseline enrollment and every two years thereafter to collect updated lifestyle and medical information. Diet was assessed using validated food frequency questionnaires every four years. The follow-up rates of the two cohorts had been 95.4% in the NHS and 95.9% in the HPFS.

Body shape assessment
---------------------

In 1988 participants in both cohorts were asked to choose one of the nine pictorial body diagrams (somatotypes) developed by Stunkard et al that best depicted their body shape at ages 5, 10, 20, 30, and 40 years.[@ref19] We have assessed the validity of this measure of body shape in early life among 181 participants aged 71-76 years in the Third Harvard Growth Study.[@ref20] We compared participants' recalled somatotypes with their measured BMI at approximately the same ages. The Pearson correlation coefficients for age 5, 10, and 20 were 0.60, 0.65, and 0.66 in women and 0.36, 0.66, and 0.53 in men.[@ref20]

Participants reported their height on the baseline questionnaire and provided their current body weight on biennial follow-up questionnaires. We used these data to calculate their BMI at age 30, 40, and 50. To minimize random variation, we used the average BMI at each of these ages plus/minus 3 years. For example, we used the average BMI from age 37 to 43 to represent the BMI for age 40. Because some participants were already at an older age at baseline, the BMI data were not complete in all participants (see supplementary methods). In addition, participants were asked to recall their body weight at age 18 in 1980 in the NHS and at age 21 in 1986 in the HPFS, as previously described.[@ref21] We used these data to calculate the BMI at adolescence.

Because the somatotype data were queried up to age 40, to better characterize the trajectory of body shape from early through middle life we used participants' BMI at age 50 as a surrogate for their body shape at that age. To convert BMI to the same scale as somatotypes (ranging from 1 to 9), we used a proportional odds mixed effects model by linking the BMI to the somatotype data at younger ages and then used this model to predict the somatotype at age 50 on the basis of the BMI at that age. More details about model development and prediction are provided in the supplementary methods.

Ascertainment of death
----------------------

We identified deaths from state statistics records, the National Death Index, next of kin, and the postal system.[@ref22] Cause of death was identified from death certificates or review of medical records by physicians. For this analysis, we assessed all cause mortality and death from cardiovascular disease (ICD-8 (international classification of diseases, eighth revision), codes 390 to 458), coronary heart disease (codes 390 to 429, 440 to 458), stroke (codes 430 to 438), cancer (codes 140 to 207 (colorectum 153, 154; pancreas 157; breast 174; endometrium 182; prostate 185)), and other causes.

Statistical analysis
--------------------

Among participants who provided somatotype data for at least four different ages, we excluded those who died or had a history of diabetes, cardiovascular disease, or cancer before age 50. We included a total of 81 477 women from the NHS and 37 163 men from the HPFS in the trajectory analysis (see flowchart in supplementary figure A). We used a group based modeling approach implemented by SAS Proc Traj to identify subgroups within each cohort that shared a similar underlying trajectory of body shape from age 5 up to 50.[@ref23] [@ref24] Details about trajectory analysis have been described elsewhere.[@ref25] Briefly, the longitudinal body shape data were fitted by maximum likelihood method as a mixture of multiple latent trajectories in a censored normal model with a polynomial function of age.[@ref24] We used the bayesian information criterion to determine the optimal number and shapes of trajectory groups through a two stage approach.[@ref26] The model with five trajectories and a cubic function of age showed the best fit to the data. We named the trajectories on the basis of the visual pattern of change in body shape over age and estimated the mean body shape levels for each trajectory at each age from the final model. We then calculated the posterior predicted probability for each participant of being a member of each of the five trajectories and assigned participants into the trajectory to which their posterior probability of membership was greatest. The average posterior probability for each trajectory was 0.91, 0.97, 0.85, 0.87, and 0.91 in women and 0.85, 0.92, 0.88, 0.88, and 0.93 in men, indicating a good discrimination of our trajectory assignment.

We then calculated the 15 year risk of death in each of the trajectory groups by using the product limit method and assessed the association of trajectories with all cause and cause specific mortality. To minimize the influence of reverse causation arising from undiagnosed illness induced weight loss, we allowed for a 10 year lag period; thus follow-up time was calculated from age 60 to the age of death or the end of the study period (1 June 2012 for the NHS and 31 January 2012 for the HPFS), whichever came first. A total of 80 266 women and 36 622 men contributing 1 300 351 and 541 066 person years through a median of 15 and 16 years of follow-up, respectively, were included in the primary analysis. We used Cox proportional hazards model to estimate hazard ratios and 95% confidence intervals of death in relation to trajectory groups, using the lean-stable group as the reference. We adjusted for several potential predictors for survival to control for confounding, and more details about covariate assessment are described in the supplementary methods. We did stratified analysis according to smoking status. Given the critical role of obesity in type 2 diabetes that may further increase risk of cardiovascular disease and cancer, we also examined the joint association of trajectory and history of type 2 diabetes with mortality. Because participants with a history of diabetes before age 50 had already been excluded, this analysis included only diabetes that was diagnosed after age 50 and treated it as a time varying variable. We used a likelihood ratio test to calculate P values for interaction by smoking and history of diabetes.

We used SAS 9.4 for all analyses. All statistical tests were two sided, and we considered P\<0.05 to be statistically significant.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in dissemination.

Results
=======

Through group based trajectory modeling, we identified five distinct trajectories of body shape from age 5 to 50 among 80 266 women and 36 622 men. Figure 1[](#f1){ref-type="fig"} shows the estimated mean body shape levels in the five trajectories at each age: 35% (28 302) of women and 25% (9086) of men maintained a lean, albeit slightly increasing, body shape throughout life (lean-stable group); 29% (23 013) of women and 17% (6221) of men started lean and then experienced a moderate increase in body shape (lean-moderate increase group); 11% (8815) of women and 17% (6241) of men started lean and then gained a substantial amount of weight (lean-marked increase group); 19% (15 475) of women and 28% (10 164) of men started with a medium body shape and then maintained or gained some weight over time (medium-stable/increase group); and 6% (4661) of women and 13% (4910) of men started heavy and then maintained or gained weight (heavy-stable/increase group).

![**Fig 1** Trajectories of body shape by age in women (top) and men (bottom). Mean body shape levels on y axis were estimated from trajectory models. Mean body mass index (BMI) at age 50 is shown for each trajectory group](sonm031059.f1_default){#f1}

As shown in table 1[](#tbl1){ref-type="table"}, BMI in each trajectory tracked well from adolescence to late adulthood. For example, in women, the mean BMI in the lean-stable group remained below 24 over the life course, whereas the mean BMI in the lean-marked increase group increased from 22.8 to 31.0 between age 18 and 50. We also noted that participants in the five trajectories showed distinctive lifestyle patterns: those in the lean-stable and medium-stable/increase groups were more physically active, tended to use multivitamins, and consumed a healthier diet than those in the other groups.

###### 

Basic characteristics of study participants at age 50 according to trajectories of body shape from age 5 to 50\*. Values are means (SDs) unless stated otherwise

  Variable                              Body shape trajectory group                                             
  ------------------------------------- ----------------------------- ------------- ------------- ------------- -------------
  **Women**                                                                                                     
  No (%) participants                   28 302 (35)                   23 013 (29)   8815 (11)     15 475 (19)   4661 (6)
  BMI at age 18†                        20.6 (2.0)                    19.6 (1.9)    22.8 (2.9)    22.7 (2.6)    26.3 (3.9)
  BMI at age 40†                        22.0 (2.2)                    22.0 (2.6)    28.4 (3.9)    23.9 (2.7)    31.3 (5.0)
  BMI at age 50†                        23.4 (2.8)                    23.6 (3.1)    31.0 (4.6)    25.3 (3.4)    33.6 (5.7)
  Height, inches                        64.5 (2.4)                    64.5 (2.5)    64.4 (2.5)    64.5 (2.4)    64.7 (2.5)
  Physical activity, METs-hours/week‡   17.6 (19.0)                   16.5 (18.3)   12.7 (15.9)   16.5 (16.9)   12.5 (14.4)
  Alcohol consumption, g/day‡           6.9 (9.8)                     6.1 (9.3)     4.1 (7.8)     6.7 (9.7)     3.9 (7.6)
  Alternative Healthy Eating Index‡     44.7 (8.9)                    43.7 (8.8)    42.9 (8.5)    45.3 (8.9)    43.6 (8.8)
  Pack years of smoking§                24.6 (20.7)                   24.1 (20.3)   24.6 (21.5)   25.8 (21.1)   26.3 (22.1)
  Smoking status, No (%):               28 138                        22 881        8763          15 397        4619
   Never                                12 441 (44)                   10 547 (46)   4258 (49)     6159 (40)     1969 (42)
   Past                                 11 459 (41)                   8918 (40)     3559 (40)     6772 (44)     2082 (45)
   Current                              4238 (15)                     3416 (14)     946 (11)      2466 (16)     568 (13)
  No (%) multivitamin use               15 008 (53)                   11 307 (49)   4406 (50)     8115 (52)     2393 (51)
  **Men**                                                                                                       
  No (%) participants                   9086 (25)                     6221 (17)     6241 (17)     10 164 (28)   4910 (13)
  BMI at age 21†                        21.0 (4.6)                    20.3 (4.5)    22.1 (5.2)    22.8 (5.3)    24.3 (6.0)
  BMI at age 40†                        23.2 (1.9)                    23.2 (2.6)    25.5 (2.9)    25.6 (2.6)    26.6 (3.2)
  BMI at age 50†                        24.1 (2.3)                    24.0 (2.6)    26.7 (3.1)    26.5 (2.9)    27.6 (3.7)
  Height, inches                        70.2 (2.6)                    70.3 (2.7)    70.1 (2.7)    70.0 (2.6)    70.1 (2.6)
  Physical activity, METs-hours/week‡   28.2 (29.7)                   26.2 (25.9)   26.0 (27.6)   28.0 (28.0)   28.1 (27.9)
  Alcohol consumption, g/day‡           11.4 (14.4)                   11.5 (14.1)   11.7 (15.1)   11.5 (15.0)   11.1 (14.3)
  Alternative Healthy Eating Index‡     41.7 (9.8)                    41.3 (9.7)    40.7 (9.6)    41.6 (9.4)    42.3 (9.6)
  Pack-years of smoking§                25.3 (19.7)                   25.5 (19.3)   26.4 (20.3)   26.2 (20.2)   28.0 (21.4)
  Smoking status, No (%):               8762                          6010          6000          9768          4725
   Never                                4429 (51)                     2656 (46)     2642 (45)     4628 (47)     2035 (42)
   Past                                 3781 (43)                     2940 (48)     2915 (48)     4471 (46)     2344 (50)
   Current                              552 (6)                       414 (6)       443 (7)       669 (7)       346 (8)
  No (%) multivitamin use               4498 (50)                     2937 (47)     2942 (47)     4986 (49)     2458 (50)

BMI=body mass index; MET=metabolic equivalent of task.

\*All variables are standardized by age at baseline (1976 for women in Nurses' Health Study and 1986 for men in Health Professionals Follow-up Study). Owing to large sample size, P values for testing difference across trajectory groups were \<0.001 for all variables listed.

†Data were not available in all participants because some participants were older than 40 or 50 at baseline or did not provide their body weight at age 18 or 21.

‡Cumulative average measurements from baseline up to age 50 years.

§Among ever smokers only.

Table 2[](#tbl2){ref-type="table"} shows the associations between trajectories and mortality in women. Overall, women in the other four trajectory groups all had a higher all cause mortality than those in the lean-stable group. After stratification by smoking, the association seemed to be much stronger among never smokers than among ever smokers (P for interaction\<0.001). Among never smokers, the multivariable adjusted hazard ratio for death from any cause was 1.08 (95% confidence interval 1.02 to 1.14) for the lean-moderate increase group, 1.43 (1.33 to 1.54) for the lean-marked increase group, 1.04 (0.97 to 1.12) for the medium-stable/increase group, and 1.64 (1.49 to 1.81) for the heavy-stable/increase group. For specific causes of death among never smokers, we found a strong positive association for cardiovascular disease, especially coronary heart disease, with hazard ratios ranging from 1.13 to 2.55 across trajectories. Mortality from stroke, cancer, and other causes was also increased for the lean-marked increase and heavy-stable/increase groups; the latter group had the highest risk (hazard ratio ranged from 1.37 to 1.82).

###### 

Hazard ratio (95% CI) of all cause and cause specific mortality from age 60 according to trajectories of body shape from age 5 to 50 among women in Nurses' Health Study\*

  Cause of death               Body shape trajectory group   P for interaction with smoking†                                                                     
  ---------------------------- ----------------------------- --------------------------------- --------------------- --------------------- --------------------- ---------
  **All cause**                                                                                                                                                  
  No of deaths (n=20 415)      6690                          6199                              2403                  3717                  1406                  
  15 year risk of death, %     11.8                          12.4                              16.7                  12.7                  19.7                  
  All                          1 (reference)                 1.05 (1.01 to 1.09)               1.29 (1.23 to 1.35)   1.05 (1.01 to 1.09)   1.48 (1.39 to 1.57)   \<0.001
  Never smokers                1 (reference)                 1.08 (1.02 to 1.14)               1.43 (1.33 to 1.54)   1.04 (0.97 to 1.12)   1.64 (1.49 to 1.81)   
  Ever smokers                 1 (reference)                 1.04 (0.99 to 1.08)               1.21 (1.14 to 1.28)   1.05 (1.00 to 1.10)   1.40 (1.30 to 1.50)   
  **Cardiovascular disease**                                                                                                                                     
  No of deaths (n=3953)        1176                          1183                              565                   676                   353                   
  15 year risk of death, %     2.1                           2.5                               4.2                   2.3                   5.7                   
  All                          1 (reference)                 1.10 (1.01 to 1.19)               1.65 (1.49 to 1.82)   1.08 (0.99 to 1.19)   2.00 (1.77 to 2.25)   0.16
  Never smokers                1 (reference)                 1.24 (1.08 to 1.42)               1.77 (1.51 to 2.09)   1.13 (0.95 to 1.33)   2.30 (1.88 to 2.81)   
  Ever smokers                 1 (reference)                 1.02 (0.92 to 1.13)               1.58 (1.39 to 1.80)   1.06 (0.94 to 1.19)   1.85 (1.59 to 2.15)   
  **Coronary heart disease**                                                                                                                                     
  No of deaths (n=2771)        788                           797                               446                   476                   264                   
  15 year risk of death, %     1.5                           1.8                               3.5                   1.6                   4.4                   
  All                          1 (reference)                 1.10 (1.00 to 1.22)               1.91 (1.70 to 2.15)   1.14 (1.01 to 1.27)   2.17 (1.89 to 2.50)   0.15
  Never smokers                1 (reference)                 1.27 (1.08 to 1.49)               1.96 (1.61 to 2.38)   1.16 (0.95 to 1.42)   2.55 (2.01 to 3.23)   
  Ever smokers                 1 (reference)                 1.02 (0.90 to 1.15)               1.90 (1.64 to 2.20)   1.12 (0.98 to 1.28)   2.00 (1.68 to 2.38)   
  **Stroke**                                                                                                                                                     
  No of deaths (n=1182)        388                           386                               119                   200                   89                    
  15 year risk of death, %     0.6                           0.7                               0.7                   0.6                   1.4                   
  All                          1 (reference)                 1.08 (0.94 to 1.25)               1.09 (0.88 to 1.34)   0.98 (0.83 to 1.16)   1.62 (1.28 to 2.04)   0.31
  Never smokers                1 (reference)                 1.18 (0.94 to 1.49)               1.41 (1.04 to 1.91)   1.06 (0.79 to 1.43)   1.82 (1.24 to 2.66)   
  Ever smokers                 1 (reference)                 1.03 (0.86 to 1.23)               0.89 (0.67 to 1.18)   0.93 (0.76 to 1.15)   1.52 (1.13 to 2.03)   
  **Cancer**                                                                                                                                                     
  No of deaths (n=6744)        2284                          2075                              708                   1273                  404                   
  15 year risk of death, %     6.0                           6.3                               7.1                   6.3                   8.0                   
  All                          1 (reference)                 1.04 (0.98 to 1.10)               1.13 (1.04 to 1.23)   1.03 (0.97 to 1.11)   1.24 (1.11 to 1.38)   0.27
  Never smokers                1 (reference)                 1.04 (0.93 to 1.15)               1.26 (1.09 to 1.44)   1.08 (0.95 to 1.23)   1.37 (1.14 to 1.65)   
  Ever smokers                 1 (reference)                 1.04 (0.96 to 1.11)               1.07 (0.96 to 1.19)   1.02 (0.94 to 1.10)   1.18 (1.04 to 1.34)   
  **Other causes**                                                                                                                                               
  No of deaths (n=9718)        3230                          2941                              1130                  1768                  649                   
  15 year risk of death, %     4.1                           4.2                               6.4                   4.8                   7.5                   
  All                          1 (reference)                 1.04 (0.99 to 1.09)               1.27 (1.19 to 1.37)   1.04 (0.99 to 1.11)   1.45 (1.33 to 1.58)   0.003
  Never smokers                1 (reference)                 1.04 (0.96 to 1.13)               1.44 (1.29 to 1.59)   0.99 (0.89 to 1.09)   1.59 (1.38 to 1.82)   
  Ever smokers                 1 (reference)                 1.04 (0.97 to 1.11)               1.17 (1.06 to 1.28)   1.07 (1.00 to 1.15)   1.38 (1.24 to 1.54)   

\*Follow-up started at age 60. Hazard ratios were estimated from age stratified Cox proportional hazards model adjusted for age (continuous), height (continuous), race (non-white or white), pack years of smoking (0, 1-\<6, 6-≤20, or \>20), family history of cancer (yes or no), history of lower gastrointestinal endoscopy (yes or no; for analysis of total cancer), multivitamin use (yes or no), regular aspirin/non-steroidal anti-inflammatory drug use (yes or no), history of physical examination (yes and for screening, yes and for symptoms, or no), mammography (yes and for screening, yes and for symptoms, or no; for analysis of total cancer), menopausal hormone therapy (past use, current use, or no), physical activity (in fifths), alcohol consumption (0-\<0.5, 0.5-\<2, 2-\<8, or ≥8 g/day), and Alternate Healthy Eating Index dietary score (in fifths).

†Likelihood ratio test with four degrees of freedom was used to compare model with product terms between smoking (binary: ever *v* never smoking) and trajectory groups (indicator variables for four non-reference groups) against model without these terms.

In men, compared with the lean-stable group, the risk of death was increased for the lean-marked increase (hazard ratio 1.14, 1.08 to 1.20), medium-stable/increase (1.06, 1.01 to 1.11), and heavy-stable/increase groups (1.16, 1.10 to 1.23) (table 3[](#tbl3){ref-type="table"}). As in women, the association for the heavy-stable/increase group was stronger among never smokers than ever smokers (P for interaction=0.06). For cause specific mortality among never smokers, men in the lean-marked increase and heavy-stable/increase groups had higher risk of death from cardiovascular and other causes, with hazard ratios ranging from 1.05 to 1.45. Interestingly, we found a stronger association with stroke mortality among ever smokers than never smokers (P for interaction=0.008). We found no association for cancer mortality in either the overall or the smoking stratified analysis.

###### 

Hazard ratio (95% CI) of all cause and cause specific mortality from age 60 according to trajectories of body shape from age 5 to 50 among men in Health Professionals Follow-up Study\*

  Cause of death               Body shape trajectory group   P for interaction with smoking†                                                                     
  ---------------------------- ----------------------------- --------------------------------- --------------------- --------------------- --------------------- -------
  **All cause**                                                                                                                                                  
  No of deaths (n=14 943)      3541                          2958                              2982                  3723                  1739                  
  15 year risk of death, %     20.3                          22.2                              27.2                  22.4                  24.1                  
  All                          1 (reference)                 1.03 (0.98 to 1.08)               1.14 (1.08 to 1.20)   1.06 (1.01 to 1.11)   1.16 (1.10 to 1.23)   0.06
  Never smokers                1 (reference)                 0.95 (0.88 to 1.03)               1.11 (1.02 to 1.20)   1.01 (0.94 to 1.09)   1.19 (1.08 to 1.32)   
  Ever smokers                 1 (reference)                 1.07 (1.01 to 1.14)               1.15 (1.09 to 1.23)   1.09 (1.03 to 1.16)   1.15 (1.07 to 1.23)   
  **Cardiovascular disease**                                                                                                                                     
  No of deaths (n=4813)        1036                          959                               1037                  1210                  571                   
  15 year risk of death, %     6.8                           8.4                               11.4                  8.2                   9.6                   
  All                          1 (reference)                 1.11 (1.02 to 1.21)               1.32 (1.21 to 1.44)   1.19 (1.09 to 1.29)   1.32 (1.19 to 1.47)   0.02
  Never smokers                1 (reference)                 0.98 (0.84 to 1.13)               1.32 (1.15 to 1.52)   1.10 (0.96 to 1.26)   1.45 (1.23 to 1.72)   
  Ever smokers                 1 (reference)                 1.19 (1.07 to 1.33)               1.32 (1.19 to 1.48)   1.24 (1.12 to 1.38)   1.26 (1.11 to 1.44)   
  **Coronary heart disease**                                                                                                                                     
  No of deaths (n=3975)        840                           791                               854                   998                   492                   
  15 year risk of death, %     5.6                           6.9                               9.5                   6.5                   8.1                   
  All                          1 (reference)                 1.13 (1.02 to 1.25)               1.33 (1.21 to 1.46)   1.19 (1.09 to 1.31)   1.37 (1.22 to 1.53)   0.09
  Never smokers                1 (reference)                 1.07 (0.91 to 1.27)               1.35 (1.15 to 1.59)   1.12 (0.96 to 1.31)   1.58 (1.31 to 1.90)   
  Ever smokers                 1 (reference)                 1.16 (1.03 to 1.31)               1.31 (1.16 to 1.48)   1.23 (1.10 to 1.38)   1.27 (1.10 to 1.47)   
  **Stroke**                                                                                                                                                     
  No of deaths (n=838)         196                           168                               183                   212                   79                    
  15 year risk of death, %     1.2                           1.6                               1.9                   1.6                   1.3                   
  All                          1 (reference)                 1.03 (0.84 to 1.27)               1.25 (1.02 to 1.53)   1.11 (0.92 to 1.35)   1.00 (0.77 to 1.29)   0.008
  Never smokers                1 (reference)                 0.63 (0.45 to 0.90)               1.16 (0.86 to 1.57)   0.93 (0.69 to 1.25)   0.79 (0.51 to 1.23)   
  Ever smokers                 1 (reference)                 1.38 (1.06 to 1.79)               1.34 (1.02 to 1.76)   1.28 (0.99 to 1.66)   1.17 (0.84 to 1.63)   
  **Cancer**                                                                                                                                                     
  No of deaths (n=4098)        1022                          801                               761                   1022                  492                   
  15 year risk of death, %     8.6                           8.7                               9.5                   8.8                   8.7                   
  All                          1 (reference)                 0.96 (0.88 to 1.06)               1.01 (0.92 to 1.11)   0.99 (0.91 to 1.08)   1.07 (0.96 to 1.19)   0.27
  Never smokers                1 (reference)                 1.03 (0.88 to 1.21)               0.99 (0.84 to 1.16)   0.92 (0.79 to 1.06)   1.07 (0.89 to 1.30)   
  Ever smokers                 1 (reference)                 0.93 (0.83 to 1.04)               1.01 (0.90 to 1.14)   1.03 (0.93 to 1.15)   1.07 (0.94 to 1.22)   
  **Other causes**                                                                                                                                               
  No of deaths (n=6032)        1483                          1198                              1184                  1491                  676                   
  15 year risk of death, %     6.5                           6.9                               9.2                   7.3                   8.0                   
  All                          1 (reference)                 1.02 (0.94 to 1.10)               1.10 (1.02 to 1.19)   1.02 (0.95 to 1.09)   1.10 (1.01 to 1.21)   0.09
  Never smokers                1 (reference)                 0.90 (0.79 to 1.02)               1.05 (0.93 to 1.19)   1.01 (0.90 to 1.13)   1.10 (0.95 to 1.29)   
  Ever smokers                 1 (reference)                 1.10 (0.99 to 1.21)               1.13 (1.02 to 1.25)   1.02 (0.93 to 1.12)   1.10 (0.98 to 1.24)   

\*Follow-up started at age 60. Hazard ratios were estimated from age stratified Cox proportional hazards model adjusted for age (continuous), height (continuous), race (non-white or white), pack years of smoking (0, 1-\<5, 5-≤25, 26-≤45, or \>45), family history of cancer (yes or no), history of lower gastrointestinal endoscopy (yes or no; for analysis of total cancer), multivitamin use (yes or no), regular aspirin/non-steroidal anti-inflammatory drug use (yes or no), history of physical examination (yes and for screening, yes and for symptoms, or no), prostate specific antigen test (yes or no; for analysis of total cancer), physical activity (in fifths), alcohol consumption (0-\<5, 5-\<10, 10-\<15, 15-\<30, or ≥30 g/day), and Alternate Healthy Eating Index dietary score (in fifths).

†Likelihood ratio test with four degrees of freedom was used to compare model with product terms between smoking (binary: ever *v* never smoking) and trajectory groups (indicator variables for four non-reference groups) against model without these terms.

To test the robustness of our findings to participants with modest trajectory assignment, we excluded 14 107 women and 8019 men whose trajectory assignment probability was below 0.80. Despite the compromised statistical power, the trajectory-mortality associations were similar (supplementary table A).

We then assessed major cancers that have been associated with obesity (supplementary table B). Again, the trajectory-mortality associations were generally stronger among never smokers. Compared with the lean-stable group, the hazard ratio for postmenopausal breast cancer was 1.16 (1.00 to 1.35) for the lean-moderate increase group, 1.06 (0.84 to 1.32) for the lean-marked increase group, 0.90 (0.74 to 1.08) for the medium-stable/increase group, and 0.79 (0.56 to 1.11) for the heavy-stable/increase group. The heavy-stable/increase group had a higher mortality from cancers in the endometrium (hazard ratio 3.15, 1.96 to 5.07), pancreas (women: 2.15, 1.49 to 3.12; men: 1.15, 0.79 to 1.66), and colorectum (women: 1.42, 0.99 to 2.03; men: 1.06, 0.74 to 1.53), although some of the confidence intervals contained one. We found no association for prostate cancer.

We further examined the joint associations of trajectory and history of diabetes with mortality among never smokers. Because the medium-stable/increase group had similar mortality to the lean-moderate increase group, we combined these two groups to maximize statistical power. Also, because the association patterns were largely similar in the two cohorts (supplementary table C), we presented the pooled results for women and men by using the random effects meta-analysis approach.[@ref27] As shown in figure 2[](#f2){ref-type="fig"}, the risk of death from any cause, cardiovascular disease, and cancer all generally increased in a gradual manner from the lean-stable, lean/medium-moderate increase, lean-marked increase, to the heavy-stable/increase groups among the stratums with or without history of diabetes. However, the increase was more pronounced among participants with type 2 diabetes (P for interaction 0.15, 0.49, and 0.01 for each of the three outcomes). Compared with participants who were in the lean-stable group and not diagnosed as having type 2 diabetes, those in the heavy-stable/increase trajectory who also had a history of diabetes were at the highest risk, and the multivariable adjusted hazard ratio was 1.84 (1.11 to 3.04) for all cause mortality, 2.60 (1.76 to 3.77) for cardiovascular mortality, and 2.09 (1.05 to 4.16) for cancer mortality.

![**Fig 2** Joint association of trajectories of body shape and history of type 2 diabetes with risk of all cause (top), cardiovascular (middle), and cancer mortality (bottom) among never smokers. Lean-moderate increase and medium-stable/increase groups were combined as "lean/medium-moderate increase" group owing to small number of cases. Multivariable Cox proportional hazards model was used to calculate hazard ratio within each cohort after adjustment for same set of covariates as in tables 2 and 3[](#tbl2 tbl3){ref-type="table"}. Participants were categorized into eight groups according to trajectories and history of type 2 diabetes, with those in lean-stable group and without history of type 2 diabetes as reference. Pooled results from both cohorts are shown here. P values for interaction were calculated from likelihood ratio test with three degrees of freedom by comparing model with product terms between diabetic history (binary) and trajectory groups (indicator variables for three non-reference groups) with model without these terms. P value for interaction for each individual trajectory group was also calculated by Wald test. For all cause mortality, individual P values for interaction were 0. 28 for lean/medium-moderate increase group, 0.09 for lean-marked increase group, and 0.04 for heavy-stable/increase group; corresponding P values for cardiovascular mortality were 0.21, 0.16, and 0.59 and those for cancer mortality were 0.64, 0.34, and 0.01](sonm031059.f2_default){#f2}

Discussion
==========

To our knowledge, this is the first study to investigate adiposity throughout early and middle life in relation to mortality. We used a trajectory approach to identify distinct subgroups of participants with similar evolution of body shape over the life course in two large cohort studies with standardized data collection for two to three decades. By comparing mortality risk between trajectory subgroups, we found that participants who remained heavy from age 5 to 50 had the highest risk of death, whereas those who maintained a stably lean body shape had the lowest mortality. Compared with the latter group, even those who were lean in childhood or adolescence but gained weight in middle life were at higher risk of mortality. This increased risk was more striking among never smokers than among ever smokers. Our findings provide further scientific rationale for recommendations of weight management, especially avoidance of weight gain in middle life, for long term health benefit.

Comparison with other studies
-----------------------------

The unique advantage of our trajectory approach over traditional analysis is its ability to map the developmental course and classify people into distinct, mutually exclusive groups. This not only helps to conceptualize the growth pattern of body shape but also allows us to probe into the population heterogeneity in the susceptibility of change in body shape over the life course, which has great implications for future research. For example, further studies should examine the relative contributions of people's genetics and behaviors to their trajectory profiles. Such investigations will provide critical insights into tailored prevention strategies. For example, the heavy-stable/increase group may have a larger genetic component, whereas the lean-marked increase group may be more behaviorally oriented. If this is the case, public health strategies of behavioral change should be targeted toward the latter group.[@ref28]

The continuous process of body growth makes it challenging to determine whether the mortality risk associated with early life obesity is due to obesity in this young age or to obesity tracking into adulthood. Most previous studies have attempted to answer this question by statistical adjustment for adulthood BMI when examining the relation between childhood or adolescent adiposity and mortality. Inconsistent findings have been reported using this approach: some studies found that the association between obesity in adolescents and higher mortality was explained by adulthood BMI,[@ref29] but others observed that the increased mortality in overweight and obese adolescents was, at least partly, independent of BMI in adulthood.[@ref16] [@ref30] [@ref31] However, this approach may represent an over-adjustment, as adulthood BMI may be a mediator for the effect of adiposity at a young age on risk of disease in adulhoodt.[@ref12] Moreover, adjustment for adulthood BMI controls not only for adult body size but also for the change in body weight from young age to adulthood. Determining whether it is early life adiposity or weight gain that is associated with the outcome is therefore difficult.[@ref32]

In contrast, instead of assessing early and late life adiposity separately, our trajectory approach respects the continuity of body growth and answers a more tangible question about the relative mortality of people who experienced different developmental courses of body shape. We found that, compared with those who maintained a lean body shape, people with a heavy body shape throughout life had a substantially increased mortality. Of note, the relative risk estimates were stronger in women than in men, although strict comparison between the two sexes is difficult because the trajectories were created within each cohort separately and sex specific reference groups were used in the analysis. Better performance of the pictograms in assessing body shape in women (see Methods) may have contributed to the stronger results than in men. Another explanation may be related to the much higher BMI in the heavy-stable/increase group in women than in men (for example, mean BMI at age 50: 33.6 *v* 27.6; table 1[](#tbl1){ref-type="table"}). More interestingly, we found that even people who were lean in early life but gained weight later were at higher risk of mortality, and the heavier the people became in middle adulthood the higher their risk was. These findings indicate a critical deleterious effect of weight gain in middle life, which has been associated with a range of cardiometabolic abnormalities, such as atherogenic lipid profile, insulin resistance, systemic inflammation, lower adiponectin, and higher leptin.[@ref33] Accordingly, weight gain from adolescence throughout adulthood has been linked to higher risks of diabetes, cardiovascular disease, and cancers in the colorectum, breast, and pancreas, as well as premature death.[@ref21] [@ref34] [@ref35] [@ref36] [@ref37] In contrast, lifestyle based weight loss interventions have been shown to result in favorable changes in cardiometabolic risk factors and potentially lower mortality.[@ref38] [@ref39] [@ref40]

Smoking is an important risk factor for many diseases and premature death, but smokers generally have a lower BMI than non-smokers.[@ref41] Thus, smoking may significantly confound and attenuate the association between body weight and mortality.[@ref42] Consistent with previous studies,[@ref5] [@ref43] we found that body shape trajectory was more strongly associated with mortality among never smokers than among ever smokers. This difference seemed to be more striking in women than in men, which may be a result of the higher proportion of current smokers among women than among men (14% *v* 7%) in our cohorts. Moreover, some, albeit inconsistent, evidence suggests a greater metabolic influence of smoking in women than men and that women tend to gain more weight after smoking cessation than men.[@ref41] [@ref44] [@ref45] Therefore, excluding smokers from the analysis may have a larger effect on the trajectory-mortality associations in women than in men. Intriguingly, for stroke, the trajectory-mortality association in men was stronger among ever smokers than among never smokers, especially for the lean-moderate or marked increase groups. Given the paucity of data on the smoking-obesity interaction with stroke mortality, further studies are needed to assess whether smoking may interact with weight gain to influence risk and progression of stroke.

Another methodological problem with examination of the obesity-mortality relation is related to reverse causation from pre-existing illnesses (for example, chronic obstructive pulmonary disease and undiagnosed cancer) that can result in weight loss and, at the same time, elevate patients' risk of death. Therefore, failing to tackle this problem may lead to an attenuated association or even a spurious inverse association between body weight and mortality. For example, this reverse causation phenomenon has been suggested to have contributed to the lower risk of mortality associated with overweight reported in the recent meta-analysis.[@ref8] Excluding participants with chronic conditions at baseline enrollment may help to abate, but hardly eliminates, this problem. In this study, we adopted a 10 year lag period for follow-up of death after assessment of trajectory to minimize reverse causation. We found that a heavy trajectory was associated with an increased risk of mortality even from causes other than cardiovascular disease or cancer (for example, respiratory or neurodegenerative disease), conditions that are likely to cause significant weight loss long before diagnosis in older people and are thus more sensitive to reverse causation.

We also observed an interaction between body shape trajectory and history of type 2 diabetes. People who had both a heavy body shape and a history of diabetes were at substantially higher risk of death than those who did not have either of the conditions. Diabetes is an important risk factor for cardiovascular disease. Increasing evidence also relates diabetes to a higher risk of cancer, including cancers of the pancreas, endometrium, liver, colorectum, and breast, possibly by mechanisms related to hyperinsulinema, hyperglycemia, and chronic inflammation.[@ref46] Furthermore, some studies found that diabetes may increase mortality in patients with cancer.[@ref47] Patients with cancer and pre-existing diabetes had a higher mortality than their non-diabetic counterparts, even after adjustment for BMI.[@ref48] [@ref49] Taken together, these data indicate that diabetes may influence risk of disease and death above and beyond the risk conferred by excess body weight.

Strengths and limitations of study
----------------------------------

Our study takes advantage of the rigorous follow-up of two well established cohorts and assessed a wide range of causes of death in addition to overall mortality. The trajectory method we used also provides an attractive alternative to traditional analysis by integration of exposure data collected across the lifespan.[@ref25] [@ref50] Although this approach has previously been used to assess the association of obesity with mortality, these studies collected data only after age 50 and were thus unable to capture any effect that early life body shape may exert.[@ref51] [@ref52] In addition, we took great care to minimize several methodological problems to provide solid evidence for the influence of body shape over the life course on mortality. Given the advancement of technology, especially the growing use of electronic medical records,[@ref53] trajectory assessment will conceivably have an improved accuracy and may not be an overwhelming task for clinical practitioners to perform in the future. Therefore, further studies are needed to determine whether assessing people's trajectory in clinical settings would produce significantly more information than just measuring BMI, by comparing clinically relevant measures (such as predictive capability) and also taking into account the cost associated with each tool.

Several limitations of the study need to be noted as well. Firstly, body shape assessed by recalled somatotype is subject to measurement error. However, given our prospective design, any error would have probably attenuated the observed association. Admittedly, a study to prospectively measure participants' body size across the lifespan and then follow them up for death would be ideal. Nevertheless, practical constraints probably make such study unfeasible. Secondly, a limited number of trajectories were derived that may not accurately reflect each person's profile of body shape. However, the good discrimination of our trajectory building model and well tracked change in BMI across trajectories indicate that these trajectories can parsimoniously summarize the predominant features of lifetime body shape in our population without a significant loss of information. Additionally, the fact that we obtained similar results after excluding participants with suboptimal trajectory assignment was reassuring. Thirdly, our study participants were all health professionals. However, the adiposity-mortality relation we observed is unlikely to differ substantially from that in the general population. On the other hand, the homogeneity of our study population helps to minimize the likelihood of uncontrolled confounding.

Conclusions
-----------

We found that heavy body shape throughout early and middle life, especially a weight increase in middle life, was associated with higher mortality. In contrast, people who maintained a stably lean body shape had the lowest mortality. These results indicate the health benefit of weight management across the lifespan.

### What is already known on this topic

1.  Although high body mass index in adulthood has been linked to increased risk of mortality, the relation between body size over the life course and mortality is still unknown

### What this study adds

1.  This work represents the first effort to systematically assess the association of body shape throughout early and middle life with mortality risk by using a life course approach

2.  Heavy body shape from age 5 up to 50, especially an increase in middle life, was associated with higher mortality; in contrast, people who maintained a stably lean body shape had the lowest mortality

3.  These results indicate the importance of weight management across the lifespan for health benefit
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